Gerald R. Connor
Mr. Connor is the Chairman of Cumberland Private Wealth Management Inc., which currently manages assets in excess of $2.0 billion for primarily high net worth investors. Prior to founding Cumberland Private Wealth Management Inc. in 1997, Mr. Connor was President of Connor, Clark & Company Ltd. (1977 to 1997) and Chairman of the board of directors of Connor, Clark & Lunn Investment Management. Mr. Connor has over 47 years of investment experience. Mr. Connor is also a trustee of Allied Properties Real Estate Investment Trust and Chair of its audit committee.
Wilmot L. Matthews
Mr. Matthews has been involved in all aspects of investment banking by serving in various positions with Nesbitt Burns Inc. and its predecessor companies from 1964 until his retirement in September, 1996, most recently as Vice Chairman and Director. Mr. Matthews is President of Marjad Inc., a private investment company, a current member of the Investment Advisory Committee of Imperial Capital, a private equity fund manager. Mr. Matthews received his Bachelor of Arts in Math, Physics and Chemistry from the University of Toronto, his Master of Science in Economics from the London School of Economics in London, England.
Andrew joined SQI Diagnostics as Chief Financial Officer in 2004 to grow and enhance the company's financial position and corporate strategy, and joined SQI's Board of Directors in October 2013.
Prior to joining SQI, Andrew led the Corporate Finance Life Sciences group at Ernst & Young, advising private and public companies on a variety of business strategy and financial matters, including private equity offerings, mergers and acquisitions, and strategic alliances.
Andrew spent eight years researching human performance enhancement at the Defence and Civil Institute of Environmental Medicine, Canada. He holds an Honours Bachelor of Science from the University of Western Ontario, a Master's of Science from the Faculty of Medicine at the University of Toronto, and a Master's of Business Administration degree from the Rotman School of Management at the University of Toronto.
Claude was the President and CEO of SQI Diagnostics from 2007 until June of 2013. Claude continues to serve SQI as a member of the Board and plays a key leadership role. He first joined the company in 2003 to help guide commercialization. Claude brings more than two decades of senior management experience, with a primary focus in business development, strategy and operational excellence. He has consistently delivered measurable results in challenging organizations, including two successful technology turnarounds and 10+ years in Tier 1 global consulting firms driving results for Fortune 100 companies.
Claude’s past roles include Senior V.P., Client Services at Oasis Technology; V.P., Professional Services at Solect Technology; and principal with global consulting firm A.T. Kearney. Claude holds an Honors Bachelor of Science from the University of Western Ontario, is a board member with Siamons International and is the past Chairman of the Board for the Georgian College Capital Foundation.
Eric holds a law degree from the University of Toronto and an honors physics degree from the University of Waterloo. He practices law with Miller Thomson LLP in Waterloo, Ontario. Besides sitting on the SQI Diagnostics board, he also chairs the company’s compensation committee. Past board positions include two TSX companies—Schneider Corporation and 20/20 Financial Group. Eric was also V.P., Secretary and General Counsel of J.M. Schneider, a food processor based in Kitchener; V.P. and Director of Business at Gotaverken Energy Systems, a supplier of steam generating and processing equipment to the pulp, paper and agricultural sectors; and a partner at Borden & Elliot (now Borden Ladner Gervais LLP).
Mr. Eric Zwisler, a global healthcare executive, was appointed to the Board of SQI Diagnostics in June of 2018. Mr. Zwisler has been a senior executive in the healthcare business for over 30 years. Most recently he was Chairman of Cardinal Health China, a subsidiary of Cardinal Health (NYSE:CAH), a US Fortune-15 healthcare company. In addition, Mr. Zwisler is a Director of the La Jolla Institute for Allergy and Immunology, one of the world’s top-five biomedical research institutes focussed on understanding the immune response to infectious agents and cancers. And, for 12 years he was a board member of the International Federation of Pharmaceutical Wholesalers (IFPW), the international trade organization of pharmaceutical distributors, serving as Chair of that body from 2012 to 2014.